Document is current
Any future updates will be listed below
-
Authors
Bähre, Jessica
Lange, Matthias
Salaschek, Patrick
Twardella, David
Arens, Stefan
Eberhard, Frank
Barten-Neiner, Grit
Panning, Marcus
Köster, Holger
Körner-Rettberg, Cordula
Wetzke, Martin
Happle, Christine
-
Funding
Funding for this research was provided by:
Sanofi-Aventis Deutschland (PAPI, PAPI)
Deutsche Forschungsgemeinschaft (Cluster of Excellence RESIST, JRG funding, Cluster of Excellence RESIST, JRG funding)
Deutsches Zentrum für Infektionsforschung (JRG Funding)
Medizinische Hochschule Hannover (MHH)
- License Information
-
More Information
Article History
Received: 5 November 2024
Revised: 20 February 2025
Accepted: 24 February 2025
First Online: 13 March 2025
Declarations
:
: All study procedures were conducted in accordance with the Declaration of Helsinki, and all local Medical Ethics Committees of the participating centers approved the study protocol (e.g., ethics approval Hannover Medical School #9442_BO_K_2020 MHH). For the prospective data analysis, the legal guardians of all participants gave written informed consent.
: This manuscript contains no individual patient data in any form.
: The PAPI study was funded by Sanofi/AstraZeneca to MW. The funder did not influence the design of the study or the collection, analysis, and interpretation of the data or writing of the manuscript. Martin Wetzke received funding from the German Center for Infection Research (DZIF). Christine Happle received funding from the Excellence Cluster RESIST in infection research. MW received consulting and speaking fees from Novartis, GSK und Abbott.
